DUSP22 and hepatocellular carcinoma: We subsequently investigated the regulatory role of DUSP22 on the pathological progression of NASH to HCC in DUSP22HepKO and DUSP22HepOE mice treated with DEN (25 mg/kg; at 2 weeks old) and a 24-week HFHC diet, and DUSP22flox and DUSP22HepRosa mice were served as corresponding controls, respectively (Fig. 8f).